What question did this study set out to answer?

This research aims to evaluate the effectiveness and immunogenicity of an RBD-Fc mucosal vaccine against SARS-CoV-2 variants.

May 18, 2025npj VaccinesOpen Access

An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial tests an RBD-Fc mucosal vaccine that protects against SARS-CoV-2 in animal models, implying broad immunogenic potential.

This research aims to evaluate the effectiveness and immunogenicity of an RBD-Fc mucosal vaccine against SARS-CoV-2 variants.
Investigated a bivalent RBD-Fc vaccine with spike receptor-binding domains of ancestral and BQ.1.1 variants.
Administered vaccine intranasally to mice and hamsters to assess delivery and immune responses.
Measured antibody responses, including mucosal IgA, and protection from viral challenges in transgenic mice.
The vaccine generated broad antibody responses and sustained mucosal IgA for at least 3 months.
Immunised mice were protected against viral challenge with XBB.1 variant, and hamsters showed limited viral transmission.
Effective delivery to lungs via intranasal route was confirmed through ex vivo imaging.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark